Ventas, Inc. (VTR)’s director Melody Barnes Unloaded 3963 shares of the Company; Last Week Supernus Pharmaceuticals, Inc. (SUPN) Coverage

Ventas, Inc. (NYSE:VTR) Logo

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings Coverage

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 38 analyst reports since August 26, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, July 5 by Cantor Fitzgerald. FBR Capital maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday, November 20 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, September 27. Piper Jaffray downgraded the shares of SUPN in report on Monday, July 18 to “Neutral” rating. The stock has “Hold” rating by Piper Jaffray on Wednesday, February 28. Stifel Nicolaus maintained the shares of SUPN in report on Monday, July 17 with “Buy” rating. The rating was maintained by Cantor Fitzgerald on Wednesday, February 28 with “Buy”. The stock has “Hold” rating by Piper Jaffray on Friday, October 27. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Thursday, August 4 by Jefferies. The rating was initiated by FBR Capital on Wednesday, October 18 with “Buy”. See Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) latest ratings:

28/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $42.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $52.0 Maintain
01/02/2018 Broker: Berenberg Rating: Buy New Target: $66 Initiates Coverage On
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $48.0 Maintain
04/12/2017 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $47 Upgrade
20/11/2017 Broker: FBR Capital Rating: Buy New Target: $50.0 Maintain

More important recent Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news were published by: Nasdaq.com which released: “Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue” on May 08, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure”, Benzinga.com published: “Technical Perspectives on Generic Drugs Stocks — Allergan, Catalyst Pharma, Flexion Therapeutics, and Supernus …” on May 03, 2018. More interesting news about Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Harmonic, Supernus Pharmaceuticals, America First …” with publication date: April 11, 2018.

Since January 2, 2018, it had 0 insider purchases, and 9 selling transactions for $11.83 million activity. Vaughn Victor sold $1.12 million worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Wednesday, January 17. On Wednesday, January 17 the insider Bhatt Padmanabh P. sold $899,500. Shares for $2.18 million were sold by PATRICK GREGORY S on Thursday, January 11.

Investors sentiment increased to 1.1 in Q4 2017. Its up 0.12, from 0.98 in 2017Q3. It improved, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 93 reduced holdings. 43 funds opened positions while 83 raised stakes. 47.19 million shares or 3.19% less from 48.75 million shares in 2017Q3 were reported. United Serv Automobile Association holds 0.01% or 86,672 shares in its portfolio. Champlain Invest Prtnrs Limited Com has invested 0.55% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Moreover, Atlantic Tru Grp Incorporated Ltd has 0% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 251 shares. Virginia Retirement Sys Et Al owns 0.02% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 46,700 shares. Amalgamated Retail Bank has invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Ahl Ptnrs Llp holds 0.02% or 27,437 shares in its portfolio. Principal Finance Grp Inc invested in 409,824 shares or 0.02% of the stock. Farmers And Merchants Investments has invested 0% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Great West Life Assurance Com Can has 0.01% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Dekabank Deutsche Girozentrale reported 25,900 shares. Voya Investment Mgmt Ltd Liability Company invested in 0% or 56,634 shares. Moreover, Secor Advisors Lp has 0.03% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 17,577 shares. Shanda Asset owns 10,000 shares or 0.06% of their US portfolio. Brinker Capital has invested 0.02% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Braun Stacey Inc invested 0.03% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

The stock decreased 1.00% or $0.45 during the last trading session, reaching $44.65. About 584,987 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 46.59% since May 9, 2017 and is uptrending. It has outperformed by 35.04% the S&P500.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $2.31 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 41.53 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

The stock decreased 0.96% or $0.51 during the last trading session, reaching $52.84. About 2.36M shares traded. Ventas, Inc. (NYSE:VTR) has declined 23.52% since May 9, 2017 and is downtrending. It has underperformed by 35.07% the S&P500.

More recent Ventas, Inc. (NYSE:VTR) news were published by: Seekingalpha.com which released: “Ventas: Safe, Cheap, And Growing” on May 01, 2018. Also Seekingalpha.com published the news titled: “Healthcare Operators: Which Has The Best Portfolio?” on April 27, 2018. Seekingalpha.com‘s news article titled: “Ventas Is Not A Strong Buy” with publication date: April 14, 2018 was also an interesting one.

An insider of the company Ventas Inc, Melody Barnes also its director, disclosed her trade activities with the SEC on 08/05/2018. As exposed in the document, Melody had sold 3,963 shares of the company. The total insider trading trade was worth $211,505 U.S Dollars. At the time of the deal the price of a share was $53.4. Melody now owns 4,667 shares accounting for 0.00% of the Company’s market cap

Ventas, Inc., an S&P 500 company, is a leading real estate investment trust. The company has market cap of $18.96 billion. The Company’s diverse portfolio of more than 1,200 assets in the United States, Canada and the United Kingdom consists of seniors housing communities, medical office buildings, life science and innovation centers, inpatient rehabilitation and long-term acute care facilities, health systems and skilled nursing facilities. It has a 13.98 P/E ratio. Through its Lillibridge subsidiary, Ventas provides management, leasing, marketing, facility development and advisory services to highly rated hospitals and health systems throughout the United States.

Investors sentiment increased to 1.2 in Q4 2017. Its up 0.09, from 1.11 in 2017Q3. It increased, as 32 investors sold Ventas, Inc. shares while 195 reduced holdings. 74 funds opened positions while 198 raised stakes. 306.00 million shares or 2.88% less from 315.08 million shares in 2017Q3 were reported. Duff And Phelps Investment Mngmt invested in 15,700 shares. Moreover, Huntington Savings Bank has 0% invested in Ventas, Inc. (NYSE:VTR) for 3,483 shares. Profund Advsr Ltd Com holds 0.04% or 17,375 shares in its portfolio. Phocas Fincl Corp holds 0.06% of its portfolio in Ventas, Inc. (NYSE:VTR) for 12,642 shares. Louisiana State Employees Retirement Systems accumulated 21,600 shares. California-based Adelante Mgmt Ltd has invested 0.53% in Ventas, Inc. (NYSE:VTR). Cornerstone Capital Management Hldg Ltd Limited Liability Company holds 0.1% of its portfolio in Ventas, Inc. (NYSE:VTR) for 242,800 shares. Bridgewater Associates L P has invested 0.04% in Ventas, Inc. (NYSE:VTR). National Pension Service has 383,318 shares. Sandy Spring State Bank has invested 0% of its portfolio in Ventas, Inc. (NYSE:VTR). Hexavest reported 1.08M shares stake. Kempen Mngmt Nv has invested 0.61% of its portfolio in Ventas, Inc. (NYSE:VTR). Bnp Paribas Asset Mngmt reported 270,833 shares. Kentucky Retirement holds 0.09% or 21,963 shares in its portfolio. Suntrust Banks reported 152,104 shares stake.

Ventas, Inc. (NYSE:VTR) Institutional Positions Chart